Sigma-Tau Pharmaceuticals, a wholly owned subsidiary of the Sigma-Tau Group, has acquired Chenofalk from the Germany-based Dr Falk Pharma.
Chenofalk is approved in Germany for the dissolution of gallstones, and Sigma-Tau’s German affiliate, Sigma-Tau Arzneimittel, will immediately assume distribution of this important medicine, ensuring there is no interruption in availability to patients.
The acquisition of Chenofalk is important not only to ensure continued supply in Germany, but Sigma-Tau Pharmaceuticals also intends to accumulate the appropriate clinical and regulatory documentation required to support the filing of a new drug application with the FDA for the use of chenodeoxycholic acid (CDCA) in the treatment of cerebrotendinous xanthomatosis disease.
Gregg Lapointe, CEO of Sigma-Tau Pharmaceuticals, said: “We are pleased to add CDCA to Sigma-Tau’s rare disease portfolio. Sigma-Tau is committed to the development of medicines for patients with rare diseases, and the acquisition of Chenofalk provides relief to patients concerned about a disruption in supply.”